title: Patterns and frequency of the treatment of depression in persons with epilepsy.
abstract: OBJECTIVE
  Though depression is common in persons with epilepsy, it often remains undiagnosed and/or untreated. The current study aimed to determine the proportion of persons with epilepsy receiving depression-related treatment and to characterize the type of treatment received.
  
  
  METHODS
  Persons with epilepsy (n=185) from the only epilepsy clinic in a city of 1.2 million people completed questionnaires and the gold-standard Structured Clinical Interview for DSM Disorders (SCID) to assess current and past depression. Treatment for depression (pharmacological and nonpharmacological) was ascertained through patient self-report and chart review.
  
  
  RESULTS
  Of those with current depression (n=27), the majority (70.3%) were not on any depression-related treatment. In persons with current depression, nonpharmacological management was the most common treatment method, followed by treatment with psychotropic medications such as selective serotonin reuptake inhibitors. More individuals with a past history of depression but without a current episode (n=43) were treated (37.2%); it was more common for these individuals to be treated with pharmacological measures. After using an algorithm that adjusts the treated prevalence for those who are successfully treated, the adjusted proportion of depression treatment was 53.1%.
  
  
  CONCLUSIONS
  The proportion of people treated for current depression in this cohort was very low. Future studies should investigate barriers to treatment and how depression treatment can be optimized for those with epilepsy.
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Psychiatry, Mathison Center for Mental Health Research & Education, University of Calgary, 4th Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 1403 29 Street NW, Calgary, AB T2N 2T9, Canada. Electronic address: kmfiest@ucalgary.ca.
authors.forename: Kirsten M
authors.initials: KM
authors.lastname: Fiest
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Psychiatry, Mathison Center for Mental Health Research & Education, University of Calgary, 4th Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada.
authors.forename: Scott B
authors.initials: SB
authors.lastname: Patten
authors.affiliation: Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 1403 29 Street NW, Calgary, AB T2N 2T9, Canada.
authors.forename: K Chelsea
authors.initials: KC
authors.lastname: Altura
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Psychiatry, Mathison Center for Mental Health Research & Education, University of Calgary, 4th Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada.
authors.forename: Andrew G M
authors.initials: AG
authors.lastname: Bulloch
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; School of Public Health and Health Systems, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; School of Pharmacy, University of Waterloo, 10 Victoria Street South, Kitchener, ON N2G 2B2, Canada.
authors.forename: Colleen J
authors.initials: CJ
authors.lastname: Maxwell
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 1403 29 Street NW, Calgary, AB T2N 2T9, Canada.
authors.forename: Samuel
authors.initials: S
authors.lastname: Wiebe
authors.affiliation: Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 1403 29 Street NW, Calgary, AB T2N 2T9, Canada.
authors.forename: Sophia
authors.initials: S
authors.lastname: Macrodimitris
authors.affiliation: Department of Community Health Sciences, Institute for Public Health, University of Calgary, 3rd Floor TRW Building, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 1403 29 Street NW, Calgary, AB T2N 2T9, Canada.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Jetté
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D004827:Epilepsy / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors
keywords: Depression; Epidemiology; Epilepsy; Treatment